Immunotherapy of allergic bronchopulmonary aspergillosis: A clinical and experimental approach

Frontiers in Bioscience

Volumn 8, Issue SUPPL., 2003, Pages

  Svirshchevskaya, E V ^a   Kurup, V P ^b,c  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anergy; CpG; Immunity; Naked DNA; Peptides; Regulatory T cells; Review; Specific immunotherapy

Indexed keywords

ALLERGEN; ANTIFUNGAL AGENT; ANTIGEN; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; PEPTIDE DERIVATIVE; PROTEIN DERIVATIVE; RECOMBINANT DNA;

ANAPHYLAXIS; ANTIFUNGAL ACTIVITY; ASPERGILLUS FUMIGATUS; ATOPY; AUTOIMMUNITY; BRONCHOPULMONARY ASPERGILLOMA; CELL ACTIVITY; CLINICAL TRIAL; CLONAL ANERGY; CYTOKINE PRODUCTION; DRUG EFFICACY; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION PREVENTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR INTERACTION; MOLECULAR MECHANICS; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH2 CELL; ANIMAL; DESENSITIZATION; IMMUNOLOGY; LUNG ASPERGILLOSIS; METHODOLOGY;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; FUNGI;

ANIMALS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; DESENSITIZATION, IMMUNOLOGIC; HUMANS;

EID: 0347394681     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/996     Document Type: Review

References (138)

1. Mullins J., R. Harvey & A. Seaton: Sources and incidence of airborne Aspergillus fumigatus (Fres). Clin Allergy 6, 209-217 (1976)
2. Raper, K.B. & D.I. Fennell: Aspergillus fumigatus group. In The genus Aspergillus. Eds: Raper KB, Fennell DI, The William & Wilkins Co., Baltimore, Md. (1975)
3. Mullins J., P.S. Hutcheson & R.G. Slavin: Aspergillus fumigatus spore concentration in outside air: Cardiff and St Louis compared. Clin Allergy 14, 351-354 (1984)
4. Svirshchevskaya E.V. & V.P. Kurup: IgE Regulation and Pathogenesis in ABPA. Recent Res Devel Immunol 4, 103-114 (2002)
5. Gugnani H.C., K.E. Reijula, V.P. Kurup & J.N. Fink: Detection of IgG and IgE antibodies to Aspergillus fumigatus in human sera by immunogold assay. Mycopathologia 109, 33-40 (1990)
6. Skov M., T. Pressler, H.E. Jensen, N. Hoiby & C. Koch: Specific IgG subclass antibody pattern to Aspergillus fumigatus in patients with cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA). Thorax 54, 44-50 (1999)
7. van Rens M.T., R. Vernooy-Jeras, M. Merton-de Ridder, H. van Velzen-Blad & J.M. van den Bosch: Detection of immunoglobulins G and A to Aspergillus fumigatus by immunoblot analysis for monitoring Aspergillus-induced lung diseases. Eur Respir J 11, 1274-1280 (1998)
8. Andriole V.T.: Infections with Aspergillus species. Clin Infect Dis 17, S481-S486 (1993)
9. Daly P. & K. Kavanagh: Pulmonary aspergillosis: clinical presentation, diagnosis and therapy. Br J Biomed Sci 58, 197-205 (2001)
10. Garber G.: An overview of fungal infections. Drugs 61, 1-12 (2001)
11. Rolston K.V.: The spectrum of pulmonary infections in cancer patients. Curr Opin Oncol 13, 218-223 (2001)
12. Johnston R.B. Jr.: Clinical aspects of chronic granulomatous disease. Curr Opin Hematol, 8, 17-22 (2001)
13. Nicod L.P., J.C. Pache & N. Howarth: Fungal infections in transplant recipients. Eur Respir J 17, 133-140 (2001)
14. Stevens D.A., V.L. Kan, M.A. Judson, V.A. Morrison, S. Dummer, D.W. Denning, J.E. Bennett, T.J. Walsh, T.F. Patterson & G.A. Pankey: Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30, 696-709 (2000)
15. Vlahakis N.E. & T.R. Aksamit: Diagnosis and treatment of allergic bronchopulmonary aspergillosis. Mayo Clin Proc 76, 930-938 (2001)
16. Basich J.E., T.S. Graves, M.N. Baz, G. Scanlon, R.G. Hoffmann, R. Patterson & J.N. Fink: Allergic bronchopulmonary aspergillosis in corticosteroid-dependent asthmatics. J Allergy Clin Immunol 68, 98-102 (1981)
17. Knutsen A.P. & R.G. Slavin: Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Clin Rev Allergy 9, 103-118 (1991)
18. Laufer P., J.N. Fink, W.T. Bruns, G.F. Unger, J.H. Kalbfleisch, P.A. Greenberger & R. Patterson: Allergic bronchopulmonary aspergillosis in cystic fibrosis. J Allergy Clin Immunol 73(Pt 1), 44-48 (1984)
19. Taccetti G., E. Procopio, L. Marianelli & S. Campana: Allergic bronchopulmonary aspergillosis in Italian cystic fibrosis patients: prevalence and percentage of positive tests in the employed diagnostic criteria. Eur J Epidemiol 16, 837-842 (2000)
20. Wark P.A. & P.G. Gibson: Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment. Respirology 6, 1-7 (2001)
21. Judson M.A. & D.A. Stevens: Current pharmacotherapy of allergic bronchopulmonary aspergillosis. Expert Opin Pharmacother 2, 1065-1071 (2001)
22. Elphick H. & K. Southern: Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev: CD002204 (2000)
23. Salez F., A. Brichet, S. Desurmont, J.M. Grosbois, B. Wallaert & A.B. Tonnel: Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 116, 1665-1668 (1999)
24. Fromtling R.A. & H.J. Shadomy: An overview of macrophage-fungal interactions. Mycopathologia 93, 77-93 (1986)
25. Madan T., N. Arora & P.U. Sarma: Identification and evaluation of a major cytotoxin of A. fumigatus. Mol Cell Biochem 167, 89-97 (1997)
26. Shen H.D., W.L. Lin, M.F. Tam, H. Chou, C.W. Wang, J.J. Tsai, S.R. Wang & S.H. Han: Identification of vacuolar serine proteinase as a major allergen of Aspergillus fumigatus by immunoblotting and N-terminal amino acid sequence analysis. Clin Exp Allergy 31, 295-302 (2001)
27. Gifford A.H., J.R. Klippenstein & M.M. Moore: Serum stimulates growth of and proteinase secretion by Aspergillus fumigatus. Infect Immun 70, 19-26 (2002)
28. Robertson M.D., K.M. Kerr & A. Seaton: Killing of Aspergillus fumigatus spores by human lung macrophages: a paradoxical effect of heat-labile serum components. J Med Vet Mycol 27, 295-302 (1989)
29. Christin L., D.R. Wysong, T. Meshulam, S. Wang & R.D. Diamond: Mechanisms and target sites of damage in killing of Candida albicans hyphae by human polymorphonuclear neutrophils. J Infect Dis 176, 1567-1578 (1997)
30. Madan T., P. Eggleton, U. Kishore, P. Strong, S.S. Aggrawal, P.U. Sarma & K.B. Reid: Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages. Infect Immun 65, 3171-3179 (1997)
31. Maertens J., J. Verhaegen, K. Lagrou, J. Van Eldere & M. Boogaerts: Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97, 1604-1610 (2001)
32. Allen M.J., A. Laederach, P.J. Reilly & R.J. Mason: Polysaccharide recognition by surfactant protein D: novel interactions of a C-type lectin with nonterminal glucosyl residues. Biochemistry 40, 7789-7798 (2001)
33. Taramelli D., M.G. Malabarba, G. Sala, N. Basilico & G. Cocuzza: Production of cytokines by alveolar and peritoneal macrophages stimulated by Aspergillus fumigatus conidia or hyphae. J Med Vet Mycol 34, 49-56 (1996)
34. Borger P., G.H. Koeter, J.A. Timmerman, E. Vellenga, J.F. Tomee & H.F. Kauffman: Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms. J Infect Dis 180, 1267-1274 (1999)
35. Traynor T.R. & G.B. Huffnagle: Role of chemokines in fungal infections. Med Mycol 39(1), 41-50 (2001)
36. Kauffman H.F., J.F. Tomee, M.A. van de Riet, A.J. Timmerman & P. Borger: Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production. J Allergy Clin Immunol 105(Pt 1), 1185-1193 (2000)
37. Nicholson W.J., J. Slight & K. Donaldson: Inhibition of the transcription factors NF-kappa B and AP-1 underlies loss of cytokine gene expression in rat alveolar macrophages treated with a diffusible product from the spores of Aspergillus fumigatus. Am J Respir Cell Mol Biol 15, 88-96 (1996)
38. Kirschning C.J. & S. Bauer: Toll-like receptors: cellular signal transducers for exogenous molecular patterns causing immune responses. Int J Med Microbiol 291, 251-260 (2001)
39. Takeuchi O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda & S. Akira: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11, 443-451 (1999)
40. Wang J.E., A. Warris, E.A. Ellingsen, P.F. Jorgensen, T.H. Flo, T. Espevik, R. Solberg, P.E. Verweij & A.O. Aasen: Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun 69, 2402-2406 (2001)
41. Skov M., L.K. Poulsen & C. Koch: Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis. Pediatr Pulmonol 27, 74-79 (1999)
42. Hemmann S., C. Ismail, K. Blaser, G. Menz & R. Crameri: Skin-test reactivity and isotype-specific immune responses to recombinant Asp f 3, a major allergen of Aspergillus fumigatus. Clin Exp Allergy 28, 860-867 (1998)
43. Walker C., W. Bauer, R.K. Braun, G. Menz, P. Braun, F. Schwarz, T.T. Hansel & B. Villiger. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 150, 1038-1048 (1994)
44. Knutsen A.P., K.R. Mueller, A.D. Levine, B. Chouhan, P.S. Hutcheson & R.G. Slavin: Asp f I CD4+ TH2-like T-cell lines in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 94(Pt 1), 215-221 (1994)
45. Jenmalm M.C., J. Van Snick, F. Cormont & B. Salman: Allergen-induced Th1 and Th2 cytokine secretion in relation to specific allergen sensitization and atopic symptoms in children. Clin Exp Allergy 31, 1528-1535 (2001)
46. Wong C.K., C.Y. Ho, F.W. Ko, C.H. Chan, A.S. Ho, D.S. Hui & C.W. Lam: Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol 125, 177-183 (2001)
47. Lamblin C., P. Desreumaux, J. F. Colombel, A.B. Tonnel & Wallaert: Overexpression of IL-10 mRNA in gut mucosa of patients with allergic asthma. J Allergy Clin Immunol 107, 739-741 (2001)
48. Cembrzynska-Nowak M., J. Liebhart, B. Banaszek, R. Dobek, M. Bienkowska & E. Szklarz: TNF-alpha, IL-6 and IFN-gamma secreted by bronchoalveolar leukocytes isolated from patients with bronchial asthma, complicated by fungal airways infections. Arch Immunol Ther Exp (Warsz) 46, 381-386 (1998)
49. Rathore V.B., B. Johnson, J.N. Fink, K.J. Kelly, P.A. Greenberger & V.P. Kurup: T cell proliferation and cytokine secretion to T cell epitopes of Asp f 2 in ABPA patients. Clin Immunol 100, 228-235 (2001)
50. Park H.S., D.H. Nahm, H.Y. Kim, Y.J. Suh, J.W. Cho, S.S. Kim, S.K. Lee & K. S. Jung: Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen. Ann Allergy Asthma Immunol 86, 444-448 (2001)
51. Bahceciler N.N., U. Isik, I.B. Barlan & M.M. Basaran: Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 32, 49-55 (2001)
52. Leynadier F., L. Banoun, B. Dollois, P. Terrier, M. Epstein, M.T. Guinnepain, D. Firon, C. Traube, R. Fadel & C. Andre: Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 31, 988-996 (2001)
53. Pajno G.B., G. Barberio, F. De Luca, L. Morabito & S. Parmiani: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 31, 1392-1397 (2001)
54. Voltolini S., P. Modena, P. Minale, D. Bignardi, C. Troise, P. Puccinelli & S. Parmiani: Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol (Madr) 29, 103-110 (2001)
55. Adkinson N.F. Jr, P.A. Eggleston, D. Eney, E.O. Goldstein, K.C. Schuberth, J.R. Bacon, R.G. Hamilton, M.E. Weiss, H. Arshad, C.L. Meinert, J. Tonascia & B. Wheeler: A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 336, 324-331 (1997)
56. Wilson D.R., K.T. Nouri-Aria, S.M. Walker, G.B. Pajno, F. O'Brien, M.R. Jacobson, I.S. Mackay & S.R. Durham: Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 107, 971-976 (2001)
57. Moverare R., L. Elfman, E. Bjornsson & G. Stalenheim: Cytokine production by peripheral blood mononuclear cells following birch-pollen immunotherapy. Immunol Lett 73, 51-56 (2000)
58. Purello-D'Ambrosio F., S. Gangemi, R.A. Merendino, S. Isola, P. Puccinelli, S. Parmiani & L. Ricciardi: Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 31, 1295-1302 (2001)
59. Keskin G., A. Inal, R. Ali Sari, A. Sengul, M. Sahin, M. Turgay & G. Kinikli: Serum IFN-gamma and IL-10 levels before and after specific immunotherapy in patients with allergic rhinitis. Allergol Immunopathol (Madr) 27, 261-264 (1999)
60. Malling H.J. & P. Stahl Skov: Diagnosis and immunotherapy of mould allergy. VIII. Qualitative and quantitative estimation of IgE in Cladosporium immunotherapy. Allergy 43, 228-238 (1988)
61. Horst M., A. Hejjaoui, V. Horst, F.B. Michel & J. Bousquet: Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 85, 460-472 (1990)
62. Latge J.P.: Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12, 310-350 (1999)
63. Banerjee B., V.P.Kurup, P.A. Greenberger, B.D. Johnson & J.N. Fink: Cloning and expression of Aspergillus fumigatus allergen Asp f 16 mediating both humoral and cell-mediated immunity in allergic bronchopulmonary aspergillosis (ABPA). Clin Exp Allergy 31, 761-770 (2001)
64. Banerjee B., V.P. Kurup, S. Phadnis, P.A. Greenberger & J.N. Fink: Molecular cloning and expression of a recombinant Aspergillus fumigatus protein Asp f II with significant immunoglobulin E reactivity in allergic bronchopulmonary aspergillosis. J Lab Clin Med 127, 253-262 (1996)
65. Kurup V.P., P.A. Greenberger & J.N. Fink: Antibody response to low-molecular-weight antigens of Aspergillus fumigatus in allergic bronchopulmonary aspergillosis. J Clin Microbiol 27, 1312-1316 (1989)
66. Hemmann S., W.H. Nikolaizik, M.H. Schoni, K. Blaser, R. Crameri: Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol 28, 1155-1160 (1998)
67. Kurup V.P., B. Banerjee, S. Hemmann, P.A. Greenberger, K. Blaser & R. Crameri: Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA. Clin Exp Allergy 30, 988-993 (2000)
68. Kapsenberg M.L., C.M. Hilkens, E.A. Wierenga & P. Kalinski: The role of antigen-presenting cells in the regulation of allergen-specific T cell responses. Curr Opin Immunol 10, 607-613 (1998)
69. Gudmundsdottir H. & L.A. Turka: T cell costimulatory blockade: new therapies for transplant rejection. J Am Soc Nephrol 10, 1356-1365. (1999)
70. Wells A.D., M.C. Walsh, J.A. Bluestone & L.A. Turka: Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 108, 895-903 (2001)
71. Muller U., C.A. Akdis, M. Fricker, M. Akdis, T. Blesken, F. Bettens & K. Blaser: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 101, 747-754 (1998)
72. Gao J.X., J. Madrenas, W. Zeng, M.J. Cameron, Z. Zhang, J.J. Wang, R. Zhong & D. Grant: CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection. Immunology 98, 159-170 (1999)
73. Kobata T., M. Azuma, H. Yagita & K. Okumura: Role of costimulatory molecules in autoimmunity. Rev Immunogenet 2, 74-80 (2000)
74. Kosmaczewska A., L. Ciszak, D. Bocko & I. Frydecka: Expression and functional significance of CTLA-4, a negative regulator of T cell activation. Arch Immunol Ther Exp (Warsz) 49, 39-46 (2001)
75. Powell J.D., D. Bruniquel & R.H. Schwartz: TCR engagement in the absence of cell cycle progression leads to T cell anergy independent of p27(Kip1). Eur J Immunol 31, 3737-3746 (2001)
76. Holdorf A.D., O. Kanagawa & A.S. Shaw: CD28 and T cell co-stimulation. Rev Immunogenet 2, 175-184 (2000)
77. Kohno Y., K. Minoguchi, N. Oda, T. Yokoe, N. Yamashita, T. Sakane & M. Adachi: Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol 102(Pt 1), 927-934 (1998)
78. Mungan D., Z. Misirligil & L. Gurbuz: Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma - a placebo controlled study. Ann Allergy Asthma Immunol 82, 485-490 (1999)
79. Moverare R., L. Elfman, E. Bjornsson & G. Stalenheim: Cytokine production by peripheral blood mononuclear cells following birch-pollen immunotherapy. Immunol Lett 73, 51-56 (2000)
80. Faith A., C.A. Akdis, M. Akdis, H.U. Simon & K. Blaser: Defective TCR stimulation in anergized type 2 T helper cells correlates with abrogated p56(lck) and ZAP-70 tyrosine kinase activities. J Immunol 159, 53-60 (1997)
81. Latek R.R. & E.R. Unanue: Mechanisms and consequences of peptide selection by the I-Ak class II molecule. Immunol Rev 172, 209-228 (1999)
82. Svirshchevskaya E., E. Frolova, L. Alekseeva, O. Kotzareva & V.P. Kurup: Intravenous injection of major and cryptic peptide epitopes of ribotoxin, Asp f 1 inhibits T cell response induced by crude Aspergillus fumigatus antigens in mice. Peptides 21, 1-8 (2000)
83. Svirshchevskaya E.V., L.G. Alekseeva, A.N. Marchenko, N.Y. Viskova, T.M. Andronova, S.V. Benevolenskii & V.P. Kurup: Immune response modulation by recombinant peptides expressed in virus like particles. Clin Exp Immunol 127, 199-205 (2002)
84. Rolland J. & R. O'Hehir: Immunotherapy of allergy: anergy, deletion, and immune deviation. Curr Opin Immunol 10, 640-645 (1998)
85. Vrtala S., C.A. Akdis, F. Budak, M. Akdis, K. Blaser, D. Kraft & R. Valenta: T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 165, 6653-6659 (2000)
86. Oldfield W.L., A.B. Kay & M. Larche: Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 167, 1734-1739 (2001)
87. Simons F.E., M. Imada, Y. Li, W.T. Watson & K.T. Hayglass: Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 8, 1937-1945 (1996)
88. Marcotte G.V., C.M. Braun, P.S. Norma, C.F. Nicodemus, A. Kagey-Sobotka, L.M. Lichtenstein & D.M. Essayan: Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 101(Pt 1), 506-513 (1998)
89. Pene J., A. Desroches, L. Paradis, B. Lebel, M. Farce, C.F. Nicodemus, H. Yssel & J. Bousquet: Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 102(Pt 1), 571-578 (1998)
90. Haselden B.M., A.B. Kay & M. Larche: Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol 122, 229-237 (2000)
91. Ewan P.W.: New insight into immunological mechanisms of venom immunotherapy. Curr Opin Allergy Clin Immunol 1, 367-374 (2001)
92. Magnan A., V. Marin, L. Mely, J. Birnbaum, S. Romanet, P. Bongrand & D. Vervloet: Venom immunotherapy induces monocyte activation. Clin Exp Allergy 31, 1303-1309 (2001)
93. Bellinghausen I., J. Knop & J. Saloga: The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 126, 97-101 (2001)
94. Akdis C.A. & K. Blaser: Role of IL-10 in allergen-specific immunotherapy and normal response to allergens. Microbes Infect 3, 891-898 (2001)
95. Steinbrink K., E. Graulich, S. Kubsch, J. Knop & A.H. Enk: CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99, 2468-2476 (2002)
96. Zhang X., L. Izikson, L. Liu & H.L. Weiner: Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol 167, 4245-4253 (2001)
97. Wakkach A., F. Cottrez & H. Groux: Differentiation of regulatory T cells 1 is induced by CD2 costimulation. J Immunol 167, 3107-3113 (2001)
98. Jooss K., B. Gjata, O. Danos, H. von Boehmer & A. Sarukhan: Regulatory function of in vivo anergized CD4(+) T cells. PNAS U S A 98, 8738-8743 (2001)
99. Wiedermann U., B. Bohle, A. Repa, D. Kraft & C. Ebner: Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen. J Allergy Clin Immunol 104, 1015-1023 (1999)
100. Kline J.N., A.M. Krieg, T.J. Waldschmidt, Z.K. Ballas, V. Jain & T.R. Businga: CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol 104, 1258-1264 (1999)
101. Magone M.T., C.C. Chan, L. Beck, S.M. Whitcup & E. Raz: Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 30, 1841-1850 (2000)
102. Hartl A., J. Kiesslich, R. Weiss, A. Bernhaupt, S. Mostbock, S. Scheiblhofer, H. Flockner, M. Sippl, C. Ebner, F. Ferreira & J. Thalhamer: Isoforms of the major allergen of birch pollen induce different immune responses after genetic immunization. Int Arch Allergy Immunol 120, 17-29 (1999)
103. Fanta C., B. Bohle, W. Hirt, U. Siemann, F. Horak, D. Kraft, H. Ebner & C. Ebner: Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 120, 218-224 (1999)
104. Meissner N., S. Kochs, J. Coutelle, F. Kussebi, C. Baumgarten, H. Lowenstein, G. Kunkel & H. Renz: Modified T-cell activation pattern during specific immunotherapy (SIT) in cat-allergic patients. Clin Exp Allergy 29, 618-625 (1999)
105. McHugh S.M., J. Deighton, A.C. Stewart, P.J. Lachmann & P.W. Ewan: Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 25, 828-838 (1995)
106. Cardon L.R., C. Burge, D.A. Clayton & S. Karlin: Pervasive CpG supression in animal mitochondrial genomes. PNAS USA 91, 3799-3803 (1994)
107. Wild J.S. & S. Sur: CpG oligonucleotide modulation of allergic inflammation. Allergy 56, 365-376 (2001)
108. Hemmi H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda & S. Akira: A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
109. Tighe H., K. Takabayashi, D. Schwarte, G. Van Nest, S. Tuck, J.J. Eiden, A. Kagey-Sobotka, P.S. Creticos, L.M. Lichtenstein, H.L. Spiegelberg & E. Raz: Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 106(Pt 1), 124-134 (2000)
110. Marshall J.D., S. Abtahi, J.J. Eiden, S. Tuck, R. Milley, F. Haycock, M.J. Reid, A. Kagey-Sobotka, P.S. Creticos, L.M. Lichtenstein & G. Van Nest: Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol 108, 191-197 (2001)
111. Banerjee B., J.Q. Xia, D.A. Rickaby, J.D. Henderson, K.J. Kelly, J.N. Fink & V.P. Kurup: Modulation of airway inflammation by immunostimlatory CpG oligodeoxynucleotide in a murine model of allergic aspergillosis. J Allergy Clin Immunol 107, S21-S217 (2001)
112. Manickan E., K.L.Karem & B.T. Rouse: DNA vaccines - a modern gimmick or a boon to vaccinology? Crit Rev Immunol 17, 139-154 (1997)
113. Roy K., H.Q. Mao, S.K. Huang & K.W. Leong: Oral gene delivery with chitosan - DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5, 387-391 (1999)
114. Adel-Patient K., C. Creminon, D. Boquet, J.M. Wal & J.M. Chatel: Genetic immunisation with bovine beta-lactoglobulin cDNA induces a preventive and persistent inhibition of specific anti-BLG IgE response in mice. Int Arch Allergy Immunol 126, 59-67 (2001)
115. Hsu C.H., K.Y. Chua, M.H. Tao, S.K. Huang & K.H. Hsieh: Inhibition of specific IgE response in vivo by allergen-gene transfer. Int Immunol 86 1405-1411 (1996)
116. Horner A.A., M.D. Nguyen, A. Ronaghy, N. Cinman, S. Verbeek & E Raz: DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice. J Allergy Clin Immunol 106, 349-356 (2000)
117. Pinto A.R., R. Puccia, S.N. Diniz, M.F. Franco & L.R. Travassos: DNA-based vaccination against murine paracoccidioidomycosis using the gp43 gene from paracoccidioides brasiliensis. Vaccine 18, 3050-3058 (2000)
118. van Bergen J., F. Ossendorp, R. Jordens, A.M. Mommaas, J.W. Drijfhout & F. Koning: Get into the groove! Targeting antigens to MHC class II. Immunol Rev 172, 87-96 (1999)
119. Young D.A., L.D. Lowe, S.S. Booth, M.J. Whitters, L. Nicholson, V.K. Kuchroo & M. Collins: IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J Immunol 164, 3563-3572 (2000)
120. Boutin Y., D. Leitenberg, X. Tao & K. Bottomly: Distinct biochemical signals characterize agonist- and altered peptide ligand-induced differentiation of naive CD4+ T cells into Th1 and Th2 subsets. J Immunol 159, 5802-5809 (1997)
121. Ausubel L.J., K,D. Bieganowska & D.A. Hafler: Cross-reactivity of T-cell clones specific for altered peptide ligands of myelin basic protein. Cell Immunol 193, 99-107 (1999)
122. De Palma R., G. Sacerdoti, G.F. Abbate, P. Martucci & G. Mazzarella: Use of altered peptide ligands to modulate immune responses as a possible immunotherapy for allergies. Allergy 55, 56-59 (2000)
123. Cianferoni A., E. Novembre, L. Mugnaini, E. Lombardi, R. Bernardini, N. Pucci & A. Vierucci: Clinical features of acute anaphylaxis in patients admitted to a university hospital: an 11-year retrospective review (1985-1996). Ann Allergy Asthma Immunol 87, 27-32 (2001)
124. Krishnaswamy G., J. Kelley, D. Johnson, G. Youngberg, W. Stone, S.K. Huang, J. Bieber & D.S. Chi: The human mast cell: functions in physiology and disease. Front Biosci 6, D1109-1127 (2001)
125. Broide D.H. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 108, S65-71 (2001)
126. Novak N., S. Kraft & T. Bieber: IgE receptors. Curr Opin Immunol 13, 721-726 (2001)
127. Bredehorst R. & K. David: What establishes a protein as an allergen? J Chromatogr B Biomed Sci Appl 756, 33-40 (2001)
128. Takai T., A. Mori, T. Yuuki, H. Okudaira & Y. Okumura: Non-anaphylactic combination of partially deleted fragments of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Mol Immunol 36, 1055-1065 (1999)
129. Akdis C.A. & K. Blaser K. Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol 121, 261-269 (2000)
130. Tang B., B. Banerjee, P.A. Greenberger, J.N. Fink, K.J. Kelly & V.P. Kurup: Antibody binding of deletion mutants of Asp f 2, the major Aspergillus fumigatus allergen. Biochem Biophys Res Commun 270, 1128-1135 (2000)
131. Banerjee B., P.A. Greenberger, J.N. Fink & V.P. Kurup: Conformational and linear B-cell epitopes of Asp f 2, a major allergen of Aspergillus fumigatus, bind differently to immunoglobulin E antibody in the sera of allergic bronchopulmonary aspergillosis patients. Infect Immun 67, 2284-2291 (1999)
132. Kurup V.P., B. Banerjee, P.S. Murali, P.A. Greenberger, M. Krishnan, V. Hari & J.N. Fink: Immunodominant peptide epitopes of allergen Asp f 1 from the fungus Aspergillus fumigatus. Peptides 19, 1469-1477 (1998)
133. Ramachandran H., V. Jayaraman, B. Banerjee, P.A. Greenberger, K.J. Kelly, J.N. Fink & V.P. Kurup: IgE conformational epitopes of Asp f 3 a major allergen of A. fumigatus. Clin Immunol 103, 324-333 (2002)
134. Janssen E., A.J. Oosterhout, F.P. Nijkamp, W. van Eden & M.H. Wauben: The efficacy of immunotherapy in an experimental murine model of allergic asthma is related to the strength and site of T cell activation during immunotherapy. J Immunol 165, 7207-7214 (2000)
135. Kurup V.P., J.Q. Xia, R. Crameri, D.A. Rickaby, H. Y. Choi, S. Fluckiger, K. Blaser, C.A. Dawson & K.J. Kelly: Purified recombinant A. fumigatus allergens induce different responses in mice. Clin Immunol 98, 327-336 (2001)
136. Ojanen T. Class specific antibodies in serodiagnosis of farmer's lung. Br J Ind Med 49, 332-336 (1992)
137. Yamasaki H., M. Ando, W. Brazer, D.M. Center & W.W. Cruikshank: Polarized type 1 cytokine profile in bronchoalveolar lavage T cells of patients with hypersensitivity pneumonitis. J Immunol, 163, 3516-3523 (1999)
138. Wild L.G. & M. Lopez: Hypersensitivity pneumonitis: a comprehensive review. J Investig Allergol Clin Immunol 11, 3-15 (2001)